hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06314997, orgStudyIdInfo id: 2013.34, briefTitle: Dynamic Changes in Circulating Tumour Cells Protein Expression, acronym: Liquid-DRER2, statusModule overallStatus: RECRUITING, startDateStruct date: 2019-01-14, primaryCompletionDateStruct date: 2024-12-17, completionDateStruct date: 2027-12-18, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Matteo's Friends, class: OTHER, descriptionModule briefSummary: This multicenter study, randomized, controlled of blood-based biomarker-driven targhet therapy. Patients were selectedm( at Hospital San Giovanni and Celio in Rome) according to CTCs results ( CTCs-guided managment performed at University Magna Graecia) or managed by the treating clinician according to standard pathological criteria (standard management). The participants were assigned to trial groups with the use of block randomization stratified according to the enrolling center location metropolitan) and tumor stage (T3 or T4)., conditionsModule conditions: Recurrence Free Survival, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: panitumumab (EGFR inhibitors), outcomesModule primaryOutcomes measure: The primary efficacy end point was recurrence- free survival at 12 months., eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 100 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Natalia Malara, status: RECRUITING, city: Germaneto, zip: 88100, country: Italy, geoPoint lat: 38.88496, lon: 16.57673, hasResults: False
protocolSection identificationModule nctId: NCT06314984, orgStudyIdInfo id: A10040521, briefTitle: Jet Injectors Versus Conventional Anesthetic Technique in Children, statusModule overallStatus: COMPLETED, startDateStruct date: 2021-07-21, primaryCompletionDateStruct date: 2022-11-15, completionDateStruct date: 2023-03-21, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Mansoura University, class: OTHER, descriptionModule briefSummary: This clinical study was conducted to compare the needleless Comfort-in jet injector device and the conventional needle technique in terms of1. Pain level during the administration of local anesthesia in children.2. Their effectiveness during pulpotomy procedures in primary molars.Whether comfort-in jet injector device will achieve sufficient anesthesia for the procedures undertaken during pulpotomy or not when compared to the conventional technique and the pain levels of both techniques during the anesthesia step., conditionsModule conditions: Anesthesia, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, enrollmentInfo count: 76, type: ACTUAL, armsInterventionsModule interventions name: Group I A (Conventional needle syringe), interventions name: Group I B (Conventional needle syringe), interventions name: Group II A (Comfort-in Jet Injector), interventions name: Group II B (Comfort-in Jet Injector), outcomesModule primaryOutcomes measure: Pain level during the administration of local anesthesia by Wong-Baker faces pain rating scale, primaryOutcomes measure: Pain levels during pulpotomy procedures steps by Wong-Baker faces pain rating scale, primaryOutcomes measure: Pain level during administration of local anesthesia in children by FLACC scale., primaryOutcomes measure: Pain levels during pulpotomy procedures steps by FLACC scale., eligibilityModule sex: ALL, minimumAge: 4 Years, maximumAge: 7 Years, stdAges: CHILD, contactsLocationsModule locations facility: Faculty of Dentistry, Mansoura University., city: Mansoura, state: Dakahlia, zip: 35516, country: Egypt, geoPoint lat: 31.03637, lon: 31.38069, hasResults: False
protocolSection identificationModule nctId: NCT06314971, orgStudyIdInfo id: 23228/T1CR, briefTitle: Predicting Local and Distant Recurrence in T1 Colorectal Cancer, acronym: T1CR, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-15, primaryCompletionDateStruct date: 2025-03-15, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: City of Hope Medical Center, class: OTHER, descriptionModule briefSummary: Tumor recurrence significantly affects survival rates following the local resection of submucosal colorectal cancers (T1 CRC). Despite this, there are currently no reliable biomarkers established to predict recurrence in T1 CRC.This study seeks to improve the prediction of recurrence-free survival in individuals who have survived T1 CRC., conditionsModule conditions: Colorectal Cancer, conditions: Colorectal Neoplasms, conditions: Colorectal Adenocarcinoma, conditions: Colorectal Cancer Stage I, conditions: Colorectal Neoplasms Malignant, conditions: Colorectal Cancer Recurrent, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 200, type: ESTIMATED, armsInterventionsModule interventions name: Tw1CE, outcomesModule primaryOutcomes measure: Recurrence-free Survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: City of Hope Medical Center, status: RECRUITING, city: Duarte, state: California, zip: 91010, country: United States, contacts name: Ajay Goel, PhD, role: CONTACT, phone: 626-218-3452, email: AJGOEL@COH.ORG, contacts name: Takayuki Noma, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Alessandro Mannucci, role: SUB_INVESTIGATOR, contacts name: Ajay Goel, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.13945, lon: -117.97729, locations facility: Tokushima University, status: RECRUITING, city: Tokushima, country: Japan, contacts name: Mitsuo Shimada, PhD, role: CONTACT, email: mitsuo.shimada@tokushima-u.ac.jp, contacts name: Katsuki Miyazaki, role: SUB_INVESTIGATOR, contacts name: Takayuki Noma, MD, role: SUB_INVESTIGATOR, contacts name: Yuma Wada, PhD, role: SUB_INVESTIGATOR, contacts name: Mistuo Shimada, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 34.06667, lon: 134.56667, locations facility: Barcelona University, status: RECRUITING, city: Barcelona, country: Spain, contacts name: Maria Pellise, role: CONTACT, email: mpellise@clinic.cat, contacts name: Karmele Saez de Gordoa, role: SUB_INVESTIGATOR, contacts name: María Daca, role: SUB_INVESTIGATOR, contacts name: Francesc Balaguer, role: PRINCIPAL_INVESTIGATOR, contacts name: Maria Pellise, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.38879, lon: 2.15899, hasResults: False
protocolSection identificationModule nctId: NCT06314958, orgStudyIdInfo id: 23228/CENSURE, briefTitle: Stage II/III Colorectal Cancer Recurrence, acronym: CENSURE, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-03-15, primaryCompletionDateStruct date: 2025-03-15, completionDateStruct date: 2025-03-15, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: City of Hope Medical Center, class: OTHER, descriptionModule briefSummary: This study will develop an assay to predict disease recurrence in patients with stage II/III CRC after receiving adjuvant chemotherapy, using genome-wide DNA methylation., conditionsModule conditions: Colorectal Cancer, conditions: Colorectal Adenocarcinoma, conditions: Colorectal Cancer Stage II, conditions: Colorectal Cancer Stage III, conditions: Colorectal Cancer Recurrent, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: RETROSPECTIVE, enrollmentInfo count: 400, type: ESTIMATED, armsInterventionsModule interventions name: CENSURE, outcomesModule primaryOutcomes measure: Recurrence-Free Survival, secondaryOutcomes measure: Overall Survival, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: City of Hope Medical Center, status: RECRUITING, city: Monrovia, state: California, zip: 91016, country: United States, contacts name: Ajay Goel, PhD, role: CONTACT, phone: 626-218-3452, email: AJGOEL@COH.ORG, contacts name: Caiming Xu, MD, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Ajay Goel, PhD, role: PRINCIPAL_INVESTIGATOR, contacts name: Alessandro Mannucci, MD, role: SUB_INVESTIGATOR, geoPoint lat: 34.14806, lon: -117.99895, locations facility: Second Affiliated Hospital of Dalian Medical University, status: RECRUITING, city: Dalian, country: China, contacts name: Man Li, role: CONTACT, email: man_li@dmu.edu.cn, contacts name: Man Li, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 38.91222, lon: 121.60222, locations facility: Barcelona University, status: RECRUITING, city: Barcelona, country: Spain, contacts name: Francesc Balaguer, MD, PhD, role: CONTACT, email: fprunes@clinic.cat, contacts name: Francesc Balaguer, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 41.38879, lon: 2.15899, locations facility: La Paz University Hospital, status: RECRUITING, city: Madrid, country: Spain, contacts name: Marta Mendiola, role: CONTACT, email: marta.mendiola@salud.madrid.org, contacts name: Marta Mendiola, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 40.4165, lon: -3.70256, hasResults: False
protocolSection identificationModule nctId: NCT06314945, orgStudyIdInfo id: #11280-4\12-2023, briefTitle: Diagnostic Value of Recto-perineal Ultrasound in Perianal Fistula, statusModule overallStatus: COMPLETED, startDateStruct date: 2023-09-01, primaryCompletionDateStruct date: 2024-03-01, completionDateStruct date: 2024-03-01, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Zagazig University, class: OTHER_GOV, descriptionModule briefSummary: Perianal fistula is a common anal problem. It needs only surgery. MRI is the best preoperative diagnostic tool, but it is demanding as it is expensive, time consuming and needs an experienced radiologist. So, we tried to find an alternative diagnostic tool which is cheaper, time saving and accurate and comparing its preoperative reports with intraoperative findings.study was held in surgery department in Zagazig University Hospitals from September 2023 to March 2024. It included 93 patients with perianal fistula who were diagnosed clinically and radiological by trans recto-perineal ultrasound and comparing pre-operative ultrasound findings with intra-operative surgical findings., conditionsModule conditions: Perianal Fistula, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 93, type: ACTUAL, outcomesModule primaryOutcomes measure: age, primaryOutcomes measure: sex, primaryOutcomes measure: body mass index, primaryOutcomes measure: history of abscess drainage, primaryOutcomes measure: Internal opening, primaryOutcomes measure: fistula branches, primaryOutcomes measure: type fistulous tract, primaryOutcomes measure: abscess cavity, secondaryOutcomes measure: other anal disease, secondaryOutcomes measure: external openings, secondaryOutcomes measure: anal discharge, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Zagazig University Hospitals, city: Zagazig, zip: 44519, country: Egypt, geoPoint lat: 30.58768, lon: 31.502, hasResults: False
protocolSection identificationModule nctId: NCT06314919, orgStudyIdInfo id: BR-PEC-OS-401, briefTitle: A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Boryung Pharmaceutical Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The purpose of this study is to evaluate the efficacy and safety of fixed-Dose combination of Pitavastatin/Ezetimibe under the real-world condition, conditionsModule conditions: Primary Hypercholesterolemia, conditions: Mixed Dyslipidemia, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 8606, type: ESTIMATED, outcomesModule primaryOutcomes measure: Rate of reaching the target LDL Cholesterol level, eligibilityModule sex: ALL, minimumAge: 19 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ewha Womans University Seoul Hospital, status: RECRUITING, city: Seoul, country: Korea, Republic of, contacts name: Wook-Bum Pyun, M.D., Ph.D., role: CONTACT, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06314906, orgStudyIdInfo id: SHLU-2024001, briefTitle: Electroacupuncture Plus Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients With Breast Cancer, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-07, primaryCompletionDateStruct date: 2027-01-31, completionDateStruct date: 2027-03-31, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-21, sponsorCollaboratorsModule leadSponsor name: Feixue Song, class: OTHER, descriptionModule briefSummary: This study explores the effectiveness of combining electroacupuncture with olanzapine-containing four-drug antiemetic therapy to mitigate chemotherapy-induced nausea and vomiting (CINV) in patients with breast cancer. The research aims to assess the adjunctive benefits of electroacupuncture in enhancing the antiemetic effects of conventional medication, particularly in the context of highly emetogenic chemotherapy regimens. By investigating the synergistic potential of these modalities, the study seeks to provide insights into optimizing supportive care strategies for patients with breast cancer undergoing intensive chemotherapy treatment., conditionsModule conditions: Electroacupuncture, conditions: Olanzapine-contained Four-drug Antiemetic, conditions: Nausea and Vomiting, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 370, type: ESTIMATED, armsInterventionsModule interventions name: Electroacupuncture, interventions name: Antiemetic Therapy, interventions name: Sham electroacupuncture, interventions name: Antiemetic Therapy, outcomesModule primaryOutcomes measure: Proportion of Patients Free from Nausea Throughout Treatment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Second Hospital of Lanzhou University, status: RECRUITING, city: Lanzhou, state: Gansu, zip: 730000, country: China, contacts name: Feixue Song, Dr, role: CONTACT, phone: 13639336037, email: 13639336037@139.com, geoPoint lat: 36.05701, lon: 103.83987, hasResults: False
protocolSection identificationModule nctId: NCT06314893, orgStudyIdInfo id: LMCII2022-001, briefTitle: Establishing a Correlation Between HRM and UGI MM Studies, acronym: MMvsMANO, statusModule overallStatus: RECRUITING, startDateStruct date: 2022-08-24, primaryCompletionDateStruct date: 2025-07, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Lexington Health Incorporated, class: OTHER, descriptionModule briefSummary: A retrospective and prospective cohort, quantitative data collection with the goal of comparing preoperative High Resolution Manometry(HRM) results to Upper Gastrointestinal Marshmallow(UGI MM) results, in patients undergoing preoperative esophageal motility assessments. The aim of this study is to establish a correlation between HRM and UGI MM in order to create a clinically supported gold standard measurement for preoperative esophageal motility assessment., conditionsModule conditions: Esophageal Motility Disorders, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, outcomesModule primaryOutcomes measure: Determining the correlation between HRM and UGI MM assessments among preoperative candidates will provide an evidenced based evaluation strategy for establishing procedural candidacy and predicting postoperative outcomes., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Lexington Health Incorporated, status: RECRUITING, city: West Columbia, state: South Carolina, zip: 29169, country: United States, contacts name: Kimberly Pressley, role: CONTACT, phone: 803-935-8794, email: kmpressley@lexhealth.org, contacts name: Marc Antonetti, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Lori Norris, APRN, role: SUB_INVESTIGATOR, contacts name: Brandi O'Neal, RN,MSN, role: SUB_INVESTIGATOR, geoPoint lat: 33.99349, lon: -81.07398, hasResults: False
protocolSection identificationModule nctId: NCT06314880, orgStudyIdInfo id: 2022112701, briefTitle: Safety, Tolerability, and Immunogenicity of Recombinant Meningococcal Group B Vaccine (E.Coli), statusModule overallStatus: RECRUITING, startDateStruct date: 2023-07-22, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2024-12-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The research objective is to evaluate the safety and tolerability of the recombinant Group B meningococcal vaccine (E. coli) and explore its preliminary immunogenicity., conditionsModule conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: Recombinant Meningococcal Group B Vaccine (E. Coli) (low-dose), interventions name: Recombinant Meningococcal Group B Vaccine (E. Coli) (hign-dose), interventions name: Placebo control, outcomesModule primaryOutcomes measure: The incidence rate of all AEs within 0-30 days after each dose of vaccination, primaryOutcomes measure: The incidence rate of solicited AEs within 30 minutes after each dose of vaccination, primaryOutcomes measure: The incidence rate of solicited AEs within 0-14 days after each dose of vaccination, primaryOutcomes measure: The incidence rate of unsolicited AEs within 0-30 days after each dose of vaccination, primaryOutcomes measure: The incidence rate of grade 3 and higher AEs within 0-30 days after each dose of vaccination, eligibilityModule sex: ALL, minimumAge: 3 Months, maximumAge: 50 Years, stdAges: CHILD, stdAges: ADULT, contactsLocationsModule locations facility: Guangxi Zhuang Autonomous Region Center for Disease Control and Prevention, status: RECRUITING, city: Nanning, state: Guangxi, zip: 530028, country: China, contacts name: Lirong Huang, role: CONTACT, phone: +86-13978620932, geoPoint lat: 22.81667, lon: 108.31667, hasResults: False
protocolSection identificationModule nctId: NCT06314867, orgStudyIdInfo id: 20220231, briefTitle: Clinical Study on Lot-to-lot Consistency and Immune Persistence of Three Commercial Batches of PPSV23, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-01-30, primaryCompletionDateStruct date: 2024-12-30, completionDateStruct date: 2028-06-30, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-04-04, sponsorCollaboratorsModule leadSponsor name: Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd, class: INDUSTRY, descriptionModule briefSummary: The research objective is to evaluate lot-to-lot consistency and immune persistence of three commercial batches of 23 valent pneumococcal polysaccharide vaccine., conditionsModule conditions: Healthy Volunteers, designModule studyType: INTERVENTIONAL, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 990, type: ACTUAL, armsInterventionsModule interventions name: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 1), interventions name: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 2), interventions name: 23 Valent Pneumococcal Polysaccharide Vaccine (lot 3), outcomesModule primaryOutcomes measure: Geometric mean concentration (GMC) levels, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 59 Years, stdAges: ADULT, contactsLocationsModule locations facility: Sichuan Center for Disease Control and Prevention, city: Chengdu, state: Sichuan, zip: 610041, country: China, geoPoint lat: 30.66667, lon: 104.06667, hasResults: False
protocolSection identificationModule nctId: NCT06314854, orgStudyIdInfo id: P202300046, briefTitle: The Effect of Running Water Sound Listened to Patients During Hemodialysis, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-12-15, primaryCompletionDateStruct date: 2024-03-15, completionDateStruct date: 2024-03-15, studyFirstPostDateStruct date: 2024-03-18, lastUpdatePostDateStruct date: 2024-03-18, sponsorCollaboratorsModule leadSponsor name: Kırklareli University, class: OTHER, descriptionModule briefSummary: It is known that being in nature and the visual perception of nature positively affects an individual's mood and self-confidence (Bratman et al., 2012). Studies have reported that natural sounds have a positive effect in situations such as pain, anxiety, and stress (Arai et al., 2008; Thoma et al., 2018). This finding means that listening to natural sounds may be a simple and easily accessible intervention that can positively impact key human stress systems.Although many non-pharmacological methods are used in the literature to reduce the invasive pain and anxiety experienced by hemodialysis (HD) patients during cannulation, the most popular recently; However, we aimed to determine the effect of the sound of running water, which we have not yet encountered in dialysis patients, on invasive pain and anxiety experienced during fistula access., conditionsModule conditions: Hemodialysis Patients, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: SINGLE, maskingDescription: he forms were collected by dialysis unit nurses who did not know the groups the patients were assigned to. Information and training on how to collect the forms were provided to the nurses by the secondco-author. The current study was therefore performed asan assessor-blinded randomized controlled trial, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 74, type: ESTIMATED, armsInterventionsModule interventions name: Running water sound, outcomesModule primaryOutcomes measure: Pain Assessment, secondaryOutcomes measure: State and Trait Anxiety Assessment, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 65 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Aas, status: RECRUITING, city: Kırklareli, state: Center, zip: 39000, country: Turkey, contacts name: Samet Sayilan, role: CONTACT, phone: 05079404528, email: sametsayilan@hotmail.com, geoPoint lat: 41.73508, lon: 27.22521, hasResults: False